Merck and Pfizer back a Michigan startup's mission to advance tumor profiling
Dan Rhodes was leading cancer sequencing at Thermo Fisher Scientific when he noticed that, despite the rush of pharma companies developing targeted therapies, most patients weren’t getting the right testing — and therefore missing out on what could be the best treatments based on their specific tumor profile.
In 2015, he set out to change that. With the support of Thermo Fisher executives and the help of a couple experts in the field, Rhodes launched Strata Oncology to advance DNA and RNA sequencing. The team has since attracted some impressive backers, including both Pfizer and Merck. And on Wednesday, they unveiled a $90 million Series C round to build out a commercial team and fuel clinical trials for new RNA-based treatment selection tests.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.